User profiles for J. Jais
 | Jean-Philippe JaisMCU-PH, Biostatistique et Informatique Médicale, Université Paris-Descartes Verified email at parisdescartes.fr Cited by 19003 |
The case for strategic international alliances to harness nutritional genomics for public and personal health
…, JL Hartman, L He, JK Hwang, JP Jais… - British Journal of …, 2005 - cambridge.org
Nutrigenomics is the study of how constituents of the diet interact with genes, and their
products, to alter phenotype and, conversely, how genes and their products metabolise these …
products, to alter phenotype and, conversely, how genes and their products metabolise these …
[PDF][PDF] Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors
Monocytes are effectors of the inflammatory response to microbes. Human CD14 +
monocytes specialize in phagocytosis and production of reactive oxygen species and secrete …
monocytes specialize in phagocytosis and production of reactive oxygen species and secrete …
X-linked Alport syndrome: natural history in 195 families and genotype-phenotype correlations in males
JP Jais, B Knebelmann, I Giatras… - Journal of the …, 2000 - journals.lww.com
Alport syndrome (AS) is a type IV collagen hereditary disease characterized by the
association of progressive hematuric nephritis, hearing loss, and, frequently, ocular changes. …
association of progressive hematuric nephritis, hearing loss, and, frequently, ocular changes. …
X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a “European Community Alport …
JP Jais, B Knebelmann, I Giatras… - Journal of the …, 2003 - journals.lww.com
ABSTRACT. Alport syndrome (AS) is a type IV collagen hereditary disease characterized by
progressive hematuric nephritis, hearing loss, and ocular changes. Mutations in the …
progressive hematuric nephritis, hearing loss, and ocular changes. Mutations in the …
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma
… CC, PB, PG, and TWM designed the research; RAC, JI, CK, LdL, MP, FL, LX, and AM
performed research and collected and analyzed the data; FL, J.-PJ, and JI performed statistical …
performed research and collected and analyzed the data; FL, J.-PJ, and JI performed statistical …
Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion
… the p53R2 mutations and performed the protein blot and mtDNA quantification in mouse,
LM performed protein blot analysis, VS performed the modeling of ribonucleotide reductase, J.-…
LM performed protein blot analysis, VS performed the modeling of ribonucleotide reductase, J.-…
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy
Purpose Studies of diffuse large B-cell lymphoma (DLBCL) are typically evaluated by using
a time-to-event approach with relapse, re-treatment, and death commonly used as the events…
a time-to-event approach with relapse, re-treatment, and death commonly used as the events…
Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters
…, L Couronné, M Parrens, JP Jaïs… - Blood, The Journal …, 2012 - ashpublications.org
Inactivating mutations of the Ten-Eleven Translocation 2 (TET2) gene were first identified in
myeloid malignancies and more recently in peripheral T-cell lymphomas (PTCLs). In the …
myeloid malignancies and more recently in peripheral T-cell lymphomas (PTCLs). In the …
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open …
…, J Gabarre, C Bonnet, M Janvier, D Canioni, JP Jais… - The Lancet, 2011 - thelancet.com
Background The outcome of diffuse large B-cell lymphoma has been substantially improved
by the addition of the anti-CD20 monoclonal antibody rituximab to chemotherapy regimens. …
by the addition of the anti-CD20 monoclonal antibody rituximab to chemotherapy regimens. …
Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker
…, S Sibon, S Kelhef, N Vénissac, JP Jais, J Mouroux… - Clinical cancer …, 2011 - AACR
Purpose: Pathologic TNM staging is currently the best prognostic factor for non‐small cell
lung carcinoma (NSCLC). However, even in early-stage NSCLC, the recurrence rates after …
lung carcinoma (NSCLC). However, even in early-stage NSCLC, the recurrence rates after …